Summary

The 7 major Sickle Cell Disease markets reached a value of US$ 775.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,904.2 Million by 2034, exhibiting a growth rate (CAGR) of 8.5% during 2024-2034.

The Sickle Cell Disease market is expected to be driven by a strong pipeline of late-stage drugs that offer a strong efficacy and safety profile. Gene therapies represent the most promising drug candidates, although costly, they are expected to offer patients a cure that avoids a painful and risky bone marrow transplant. Furthermore, diagnosis and treatment rates for sickle cell disease have also improved significantly, creating a positive impact on the market.

Sickle Cell Disease (SCD) is a form of inherited blood disorder. Patients with Sickle cell disease have abnormal hemoglobin. This causes the red blood cells to become hard and sticky and appear like a C-shaped farm tool called a “sickle.” The sickle cells die early, resulting in a constant shortage of red blood cells. Signs and symptoms of sickle cell anemia normally appear around 6 months of age. They vary from one individual to another and may change over time. Common symptoms can include anemia, episodes of pain, swelling of hands and feet, frequent infections, delayed growth or puberty, vision problems, etc. Sickle Cell Disease is a genetic disorder that is present at birth. It is inherited when an individual receives two genes - one from both parents that code for abnormal hemoglobin.

IMARC Group’s new report "Sickle Cell Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Sickle Cell Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Sickle Cell Disease market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Sickle Cell Disease across the seven major markets. According to the report, among the seven major markets, the United States have the largest patient pool for Sickle Cell Disease and represent the largest market for Sickle Cell Disease treatment. Furthermore, the current Sickle Cell Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Sickle Cell Disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current, and Future Epidemiology Scenario
Historical, Current, and Future Performance of the Sickle Cell Disease Market
Historical, Current, and Future Performance of Various Therapeutic Categories in the Sickle Cell Disease Market
Sales of Various Drugs Across the Sickle Cell Disease Market
Reimbursement Scenario in the Sickle Cell Disease Market
Competitive Landscape:
This report also provides a detailed analysis of the current Sickle Cell Disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the Sickle Cell Disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Sickle Cell Disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Sickle Cell Disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Sickle Cell Disease market?


Epidemiology Insights

What is the size of the Sickle Cell Disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Sickle Cell Disease across the seven major markets?
What are the key factors driving the epidemiological trend of Sickle Cell Disease?
What will be the growth rate of Sickle Cell Disease patients across the seven major markets?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current marketed Sickle Cell Disease drugs and what are their market performance?
What are the key pipeline Sickle Cell Disease drugs and how are they expected to perform in the coming years?
How safe are the currently marketed Sickle Cell Disease drugs and what are their efficacies?
How safe are the late-stage pipeline Sickle Cell Disease drugs and what are their efficacies?
What are the current treatment guidelines for Sickle Cell Disease drugs across the seven major markets?
Who are the key companies in the Sickle Cell Disease market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Sickle Cell Disease market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Sickle Cell Disease - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Sickle Cell Disease - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Sickle Cell Disease - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)

8 Sickle Cell Disease - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Sickle Cell Disease Guidelines, Management and Treatment
8.2 Sickle Cell Disease Treatment Algorithm

9 Sickle Cell Disease - Unmet Needs

10 Sickle Cell Disease - Key Endpoints of Treatment

11 Sickle Cell Disease - Marketed Products
11.1 List of Sickle Cell Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Sickle Cell Disease - Pipeline Drugs
12.1 List of Sickle Cell Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. Sickle Cell Disease - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Sickle Cell Disease - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Sickle Cell Disease - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Sickle Cell Disease - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Sickle Cell Disease - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Sickle Cell Disease - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Sickle Cell Disease - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Sickle Cell Disease - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Sickle Cell Disease - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Sickle Cell Disease - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Sickle Cell Disease - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Sickle Cell Disease - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Sickle Cell Disease - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Sickle Cell Disease - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Sickle Cell Disease - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Sickle Cell Disease - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Sickle Cell Disease - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Sickle Cell Disease - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Sickle Cell Disease - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Sickle Cell Disease - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Sickle Cell Disease - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Sickle Cell Disease - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Sickle Cell Disease - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Sickle Cell Disease - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Sickle Cell Disease - Access and Reimbursement Overview

15 Sickle Cell Disease - Recent Events and Inputs From Key Opinion Leaders

16 Sickle Cell Disease Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix